BioWorld

June 26, 2007

GPC Draws $10M Up Front In Japanese Marketing Deal

One month away from an FDA panel review, GPC Biotech Inc.'s satraplatin for prostate cancer has become the subject of a $10 million license deal with Yakult Honsha Co. Ltd., for rights in Japan. (BioWorld Today) Read More

DPP-IV Inhibitor Data Abound As Januvia Competition Draws Near

Targeting Immunity, Not Invader, Key To Broad-Spectrum Antiviral

Argolyn Adds $16M In Series A For Peptide Drug Development

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...